Profound Medical Corp. PRN.TO
Nov 4, 2026, 10:10 AM EST
- YTD
- -6.04%
- 1 year
- +21.20%
- Market cap
- 369.71M
- Revenue (ttm)
- 8.98M
- EPS (ttm)
- -1.37
- Shares out
- 30.03M
- Forward P/E
- -8.70
- YTD return
- -6.04%
- 1-year return
- +21.20%
- Volume
- 23.82K
- Avg volume
- 13.94K
- Open
- 9.90
- Previous close
- 9.77
- Day's range
- 9.65 – 10.20
- 52-week range
- 6.99 – 12.11
- Beta
- 0.83
- Analysts
- Strong Buy
2Y -1.55 (-13.64%)
Key statistics
- Enterprise value
- 233.66M
- PEG ratio
- 0.00
- Price / sales
- 33.42
- Price / book
- 7.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 63.90%
- Free cash flow
- -14.79M
- Total cash
- 27.12M
- Total debt
- 6.23M
- Return on equity
- -90.17%
- Short % of float
- 0.00%
- 50-day average
- 10.80
- 200-day average
- 11.36
Analyst view
Consensus: strong buy
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.48175.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 16, 2024 | Stifel | up | Hold | Buy |
| Mar 11, 2024 | Alliance Global Partners | main | Buy | Buy |
| Mar 8, 2024 | Stifel | main | Hold | Hold |
| Jan 4, 2024 | Alliance Global Partners | main | Buy | Buy |
| Nov 28, 2023 | Stifel | init | — | Hold |
| Aug 4, 2023 | Raymond James | down | Strong Buy | Outperform |
About Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Canada
- Website
- profoundmedical.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PRN.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FIL LTD | 5.11% | 1,535,000 | 15.35M | Sep 29, 2024 |
| Gagnon Securities, LLC | 4.89% | 1,467,247 | 14.67M | Sep 29, 2024 |
| Letko, Brosseau & Associates Inc. | 3.99% | 1,198,775 | 11.99M | Sep 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 2.53% | 760,457 | 7.60M | Sep 29, 2024 |
| Timelo Investment Management Inc. | 2.50% | 751,807 | 7.52M | Sep 29, 2024 |
| Gagnon Advisors, LLC | 2.49% | 747,226 | 7.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Royce Micro-Cap Fund | 0.76% | 227,937 | 2.28M | Sep 29, 2024 |
| Royce Micro Cap Trust | 0.63% | 189,100 | 1.89M | Sep 29, 2024 |
| Royce Capital Fund-Micro-Cap Portfolio | 0.33% | 100,163 | 1.00M | Sep 29, 2024 |
| Royce Small-Cap Fund | 0.17% | 52,098 | 520.98K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 14,049 | 140.49K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional International Small Cap ETF | 0.00% | 1,188 | 11.88K | Jul 30, 2024 |